 |
|
Chemotherapy with gemcitabine delays progression of operable pancreatic cancer
September 27, 2007Barcelona, Spain: Giving pancreatic cancer patients the chemotherapy drug gemcitabine after surgery delays progression of the disease by about six months, according to new research by Japanese scientists.
The study, presented today (Thursday) at the European Cancer Conference (ECCO 14) in Barcelona, found that the drug more than doubled the average disease-free survival from 4.9 months to 11.4 months.
"We believe that a median disease-free survival of 11.4 months is an outstanding result. It means an improvement, or reduction in the risk of recurrence, of 41 percent," said the study's lead researcher, Dr Tomoo Kosuge, deputy director of the National Cancer Center Hospital in Tokyo, Japan. "That is difficult to achieve in patients with pancreatic cancer."
Pancreatic cancer has among the poorest prognoses. Most often, it has already spread by the time it is diagnosed, but in about 20 percent of patients, surgery is a viable option. However, even if it can be operated on, the cancer normally recurs and more than half of patients die within 20 months of their diagnosis. Only around 20 percent of them are still alive five years after being diagnosed.
Chemotherapy with gemcitabine is the standard treatment for advanced pancreatic cancer that cannot be operated on. As for resectable pancreatic cancer, researchers are investigating whether chemotherapy or chemoradiation might help. However, there is no universally accepted adjuvant treatment for patients whose pancreas can be removed, so mere observation after surgery is still the widely accepted approach.
In the latest study, 118 patients whose pancreatic cancer could be cut out were either given gemcitabine chemotherapy after surgery or closely monitored by doctors. Both groups were followed for more than 20 months.
The disease recurred in 72 percent of the patients getting gemcitabine, compared with 85 percent of those on observation. The overall survival, meaning survival regardless of whether the disease progressed, was better in the gemcitabine group, but those results were not statistically significant.
"In the results of our study, the lack of a significant difference in the overall survival means the observation approach was not altogether negated. We therefore propose that chemotherapy with gemcitabine, as well as observation, now be considered as optimal treatment for patients with operable pancreatic cancer," Kosuge said.
The Japanese study bolsters the findings of a German study published earlier this year that similarly found gemcitabine delays progression of the disease after surgery.
ECCO-the European CanCer Conference
Pancreatic cancer has among the poorest prognoses. Most often, it has already spread by the time it is diagnosed, but in about 20 percent of patients, surgery is a viable option. However, even if it can be operated on, the cancer normally recurs and more than half of patients die within 20 months of their diagnosis. Only around 20 percent of them are still alive five years after being diagnosed.
Chemotherapy with gemcitabine is the standard treatment for advanced pancreatic cancer that cannot be operated on. As for resectable pancreatic cancer, researchers are investigating whether chemotherapy or chemoradiation might help. However, there is no universally accepted adjuvant treatment for patients whose pancreas can be removed, so mere observation after surgery is still the widely accepted approach.
In the latest study, 118 patients whose pancreatic cancer could be cut out were either given gemcitabine chemotherapy after surgery or closely monitored by doctors. Both groups were followed for more than 20 months.
The disease recurred in 72 percent of the patients getting gemcitabine, compared with 85 percent of those on observation. The overall survival, meaning survival regardless of whether the disease progressed, was better in the gemcitabine group, but those results were not statistically significant.
"In the results of our study, the lack of a significant difference in the overall survival means the observation approach was not altogether negated. We therefore propose that chemotherapy with gemcitabine, as well as observation, now be considered as optimal treatment for patients with operable pancreatic cancer," Kosuge said.
The Japanese study bolsters the findings of a German study published earlier this year that similarly found gemcitabine delays progression of the disease after surgery.
ECCO-the European CanCer Conference
Pancreatic Cancer Current Events and Pancreatic Cancer News RSS2 new compounds show promise for eliminating breast cancer tumors
Two new compounds created by a University of Central Florida professor show early promise for destroying breast cancer tumors.
The miseries of allergies just may help prevent some cancers, study finds
There may be a silver -- and healthy -- lining to the miserable cloud of allergy symptoms: Sneezing, coughing, tearing and itching just may help prevent cancer -- particularly colon, skin, bladder, mouth, throat, uterus and cervix, lung and gastrointestinal tract cancer, according to a new Cornell study.
Cancer drugs my build and not tear down blood vessels
Scientists have thought that one way to foil a tumor from generating blood vessels to feed its growth - a process called angiogenesis - was by creating drugs aimed at stopping a key vessel growth-promoting protein. But now the opposite seems to be true.
UC Davis researchers discover Achilles' heel in pancreatic cancer
UC Davis Cancer Center researchers have discovered a metabolic deficiency in pancreatic cancer cells that can be used to slow the progress of the deadliest of all cancers.
Jefferson Department of Surgery announces new pancreas tumor registry
Charles J. Yeo, M.D., Samuel D. Gross Professor and Chair, Department of Surgery at Jefferson Medical College of Thomas Jefferson University, announces the establishment of the new Jefferson Pancreas Tumor Registry (JPTR).
Supercomputer provides massive computational boost to biomedical research at TGen
In less time than the blink of an eye, the Translational Genomics Research Institute's new supercomputer at Arizona State University can do operations equal to every dollar in the recent Wall Street bailout.
Hepatitis B exposure may increase risk for pancreatic cancer
In a first-of-its-kind finding, researchers at The University of Texas M. D. Anderson Cancer Center have discovered that exposure to the hepatitis B virus (HBV) may increase the risk of pancreatic cancer.
Study finds association between hepatitis B and pancreatic cancer
A new study has shown that evidence of past hepatitis B infection was twice as common in people with pancreatic cancer than in healthy controls. This study is the first to report an association between past exposure to the hepatitis B virus and pancreatic cancer, but researchers cautioned that more studies are necessary to evaluate the nature of the link.
Jefferson scientists deliver toxic genes to effectively kill pancreatic cancer cells
A research team, led by investigators at the Department of Surgery at Jefferson Medical College of Thomas Jefferson University and the Kimmel Cancer Center at Jefferson, has achieved a substantial "kill" of pancreatic cancer cells by using nanoparticles to successfully deliver a deadly diphtheria toxin gene.
The effective chemoradiotherapy method for pancreatic cancer
Pancreatic cancer is the fifth most common cause of cancer death in Japan. The prognosis is extremely poor because it is difficult to detect this disease in the early stage and also the postoperative incidence of recurrence is still high, and we have not had any effective treatment for inoperable patients.
More Pancreatic Cancer Current Events and Pancreatic Cancer News Articles
 | 100 Q&A About Pancreatic Cancer (100 Questions Series) by Joanne Frankel Kelvin Eileen O'Reilly EMPOWER YOURSELF! Whether you’re a newly diagnosed pancreatic cancer patient, a survivor, or a friend or relative of someone with pancreatic cancer, this book offers help. The only text to provide a doctor’s and patient’s view, 100 Questions & Answers About Pancreatic Cancer gives you authoritative, practical answers to your questions about treatment options, post-treatment quality of... |
 | My Journey With Pancreatic Cancer by Calvin E. Rains Sr. This book is shared to help all understand the cancer affecting the pancreas which is a vital organ in the digestion of food. Pancreatic cancer is one of the most deadly of cancers affecting the human body. Less than 5% of those diagnosed with Pancreatic Cancer survive the first year. This book is intended to help the patient, their families, and friends to understand the dangers and possible... |
 | Pancreatic Cancer (M.D. Anderson Solid Tumor Oncology Series) Since the previous M.D. Anderson Solid Tumor Oncology Series publication on pancreatic cancer, there have been major advances in our understanding of molecular events which underlie pancreatic cancer development, both in the sporadic and inherited forms. We have seen the development of the first mouse models that accurately recapitulate features of the human disease. Several landmark clinical... |
| 100 Questions & Answers About Pancreatic Cancer, 2nd Edition (100 Questions & Answers about . . .) by Eileen O'Reilly Empower yourself!Whether you're a newly diagnosed pancreatic cancer patient, a survivor, or friend or relative of someone with pancreatic cancer, this book offers help. The only text to provide a doctor's and a patient's view, 100 Questions & Answers About Pancreatic Cancer, Second Edition gives you authoritative, practical answers to your questions about treatment options, post-treatment quality... | |
| Pancreatic Cancer (American Cancer Society Atlas of Clinical Oncology) by John L. Cameron At present, there are approximately 28,300 new cases of pancreatic cancer in the United States. It is the fourth leading cause of cancer death in men and women. Approximately 2 out of 10 patients with cancer of the pancreas will live at least one year after the cancer is found, but only a very few will survive for five or more years. The editors have brought together a stellar team of... | |
 | Pancreatic Cancer by Daniel D. Von Hoff (Editor) Praise for the book “An outstanding text covering all aspects of pancreatic cancer, from embryology through genetics and pathology, and including all avenues of treatment. There are 112 internationally recognized authors, the book is marvelously illustrated, and is a must for all scientists and clinicians interested in neoplasms of the pancreas. It is currently the most up-to-date and... |
 | The Official Patient's Sourcebook on Pancreatic Cancer: A Revised and Updated Directory for the Internet Age by Icon Health Publications This book has been created for patients who have decided to make education and research an integral part of the treatment process. Although it also gives information useful to doctors, caregivers and other health professionals, it tells patients where and how to look for information covering virtually all topics related to pancreatic cancer (also Cancer pancreas; Pancreatic cancer), from the... |
 | Pancreatic Cancer (Recent Results in Cancer Research) Although pancreatic cancer is one of the most serious forms of cancers, the outlook for patients could be improved. The lack of clinical symptoms of early, surgically removable disease most often limits curative treatment options. The aggressive tumor cell biology, leading to a locally advanced nature of the disease and to early metastases, allows curative resection in only 20% of patients at the... |
 | Myths & Facts About Pancreatic Cancer; What You Need to Know Facts about pancreatic... |
 | Pancreatic Cancer: Methods and Protocols (Methods in Molecular Medicine) (Methods in Molecular Medicine) This ambitious collection of essential yet novel methods for pancreatic cancer research or cancer research in general features an outstanding cast of authors who are esteemed leaders in the field. The authors provide a broad range of methods for molecular, biochemical, pathological, and statistical analysis of sporadic and familial pancreatic cancer, methods that can be applied not only to basic,... |
| © 2008 BrightSurf.com |